Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx Corporation (Nasdaq: LUNG) reported a 17% increase in revenue for Q3 2020, totaling $10.6 million. The gross margin remained stable at 70.3%. U.S. revenue surged by 57% to $5.3 million, driven by the Zephyr Valve launch, while international revenue dropped 8% due to pandemic impacts. Operating expenses rose 28% to $12.8 million, leading to a net loss of $3.9 million or $1.37 per share. Pulmonx expects full-year revenue between $31.5-$32.0 million, reflecting ongoing uncertainty from COVID-19.
Pulmonx Corporation (NASDAQ: LUNG) announced its participation in two virtual investor conferences. The company will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 10:40 a.m. ET, with a live and archived webcast available on its website. Additionally, Pulmonx management will join investor meetings at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020. Pulmonx specializes in minimally invasive treatments for severe emphysema, having received FDA pre-market approval for its Zephyr Endobronchial Valve.
Pulmonx Corporation (NASDAQ: LUNG) announced that Health Care Service Corporation (HCSC) has implemented a positive coverage policy for the Zephyr Endobronchial Valve effective November 1, 2020. This policy benefits Blue Cross Blue Shield members across Illinois, Montana, New Mexico, Oklahoma, and Texas. The Zephyr Valve offers a minimally invasive treatment for severe emphysema, improving lung function and quality of life without major surgery. Over 20,000 patients have been treated with this valve globally, highlighting its significance in COPD management.
Pulmonx Corporation (NASDAQ: LUNG) will release its third-quarter financial results on November 10, 2020, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The company specializes in minimally invasive treatments for lung disease, particularly for severe emphysema/COPD patients. The Zephyr® Endobronchial Valve, part of its treatment solutions, has received FDA pre-market approval and is available in over 25 countries with more than 80,000 valves used on over 20,000 patients.
Pulmonx Corporation (Nasdaq: LUNG) recently closed its initial public offering, selling 11,500,000 shares of common stock at $19.00 per share. This includes the full exercise of underwriters' options for 1,500,000 additional shares. The gross proceeds from the offering reached approximately $218.5 million, prior to deductions for underwriting discounts and commissions. Shares began trading on The Nasdaq Global Select Market on October 1, 2020. BofA Securities and Morgan Stanley served as joint lead managers for the offering.
Pulmonx Corporation has announced the pricing of its upsized initial public offering (IPO) of 10,000,000 shares at $19.00 each, totaling gross proceeds of $190 million. The offering includes a 30-day option for underwriters to purchase an additional 1,500,000 shares. Trading on the Nasdaq under the symbol 'LUNG' will commence on October 1, 2020, with the expected close on October 5, 2020. BofA Securities and Morgan Stanley lead the offering, which was declared effective by the SEC on the same day.